公开(公告)号：EP2616084A1

公开(公告)日：2013-07-24

申请号：EP11788574.9

申请日：2011-10-10

申请人： Fernandez, Adrian, Hector, Antonio ,  Soubeiran, Chobet ,  Fernandez, Hector, Manuel

发明人： Fernandez, Adrian, Hector, Antonio ,  Soubeiran, Chobet ,  Fernandez, Hector, Manuel

IPC分类号： A61K33/24 ,  A61P33/00

CPC分类号： A61K33/245 ,  A61K9/06 ,  A61K31/29 ,  A61K31/618 ,  Y02A50/473

摘要： The present invention relates to the a bismuth-based composition, particularly involving the use of bismuth ions, particularly the Bi+3 ion, for prevention and/or treatment of the haemolytic uremic syndrome, with the invention also relating to the use of a bismuth ion in the manufacture of a medicament for the prevention and/or treatment of an infection caused by a Shiga-toxin producing Escherichia coli strain, as well as to a method for preventing and/or treating the haemolytic uremic syndrome comprising administering bismuth ions to a patient in need thereof, and a method for inhibiting dissemination of the gene encoding virulence factors of a Shiga-toxin producing Escherichia coli strain in animals and humans.

公开(公告)号：EP2265265A2

公开(公告)日：2010-12-29

申请号：EP09767132.5

申请日：2009-03-10

申请人： The Charlotte-Mecklenburg Hospital Authority

发明人： SAHA, Dhanonjoy ,  DOMENICO, Philip

IPC分类号： A61K31/095 ,  A61K31/29 ,  A61K31/285 ,  A61K33/24 ,  A61P29/00

CPC分类号： A61K31/29 ,  A61K31/095 ,  A61K31/285 ,  A61K33/24 ,  A61K33/245 ,  A61K33/36 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention provides a method for the treatment of a disease or disorder related to an inflammatory condition comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a metal and a thiol. In particular, embodiments of the present invention are directed towards methods of treating inflammatory conditions that are associated with elevated levels of free TNFα. In one embodiment, the present invention can be used to treat and/or ameliorate the effects of a wide variety of diseases or disorders related to an inflammatory condition including one or more of the following inflammation related diseases/disorders: arthritis, rheumatoid arthritis, asthma, psoriasis, systemic lupus erythematosus, inflammatory bowel syndrome, chronic obstructive respiratory diseases (COPD), fibromyalgia and the neurological diseases and disorders multiple sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, vascular dementia, epilepsy, migraines, stroke and trauma.

公开(公告)号：EP1572070A4

公开(公告)日：2009-11-04

申请号：EP02778242

申请日：2002-09-09

申请人： CLEVELAND CLINIC FOUNDATION

发明人： YI TAOLIN

IPC分类号： A61K31/29 ,  A61K31/496 ,  A61K31/555 ,  A61K38/19 ,  C12Q1/18 ,  A61K38/00 ,  A61K38/16 ,  C07K1/00

CPC分类号： A61K31/555 ,  A61K31/29 ,  A61K31/496 ,  A61K38/193 ,  A61K38/21 ,  A61K2300/00

摘要： In one embodiment, a therapeutic composition containing a pentavalent antimonial is provided. The pentavalent antimonial can be sodium stibogluconate, levamisole, ketoconazole, and pentamidine and biological equivalents of said compounds. Additionally, pentavalent antimonials that can be used in accordance with the present invention may be any such compounds which are anti-leishmaniasis agents. The therapeutic composition of this embodiment contains an effective amount of pentavalent antimonial that can be used in treating infectious diseases. The types of diseases that can be treated with the present invention include, but are not limited to, the following: diseases associated with PTPase activity, immune deficiency, cancer, infections (such as viral infections), hepatitis B, and hepatitis C. The types of cancers that the present embodiment can be used to treat include those such as lymphoma, multiple myeloma, leukemia, melanoma, prostate cancer, breast cancer, renal cancer, bladder cancer. The therapeutic composition enhances cytokine activity. The therapeutic composition may include a cytokine, such as interferon α, interferon &bgr;, interferon γ, or granulocyte/macrophage colony stimulating factor.

公开(公告)号：EP1814543A2

公开(公告)日：2007-08-08

申请号：EP05848864.4

申请日：2005-11-08

申请人： CELGENE CORPORATION

发明人： HENSEL, Jennifer, L.

IPC分类号： A61K31/4035 ,  A61K45/00 ,  A61K31/45 ,  A61P33/02 ,  A61P33/06 ,  A61P33/12

CPC分类号： A61K45/06 ,  A61K31/29 ,  A61K31/4035 ,  A61K31/45 ,  A61K31/496 ,  A61K31/573 ,  A61K31/63 ,  A61K31/65 ,  A61K31/655 ,  A61K31/7048 ,  Y02A50/491 ,  Y02A50/492 ,  A61K2300/00

摘要： Methods of treating, preventing and/or managing various protozoan parasitic disease and disorders are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone, or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with conventional anti-parasitic treatments which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

公开(公告)号：EP1572070A2

公开(公告)日：2005-09-14

申请号：EP02778242.4

申请日：2002-09-09

申请人： THE CLEVELAND CLINIC FOUNDATION

发明人： YI, Taolin

IPC分类号： A61K6/00

CPC分类号： A61K31/555 ,  A61K31/29 ,  A61K31/496 ,  A61K38/193 ,  A61K38/21 ,  Y02A50/409 ,  A61K2300/00

摘要： In one embodiment, a therapeutic composition containing a pentavalent antimonial is provided. The pentavalent antimonial can be sodium stibogluconate, levamisole, ketoconazole, and pentamidine and biological equivalents of said compounds. Additionally, pentavalent antimonials that can be used in accordance with the present invention may be any such compounds which are anti-leishmaniasis agents. The therapeutic composition of this embodiment contains an effective amount of pentavalent antimonial that can be used in treating infectious diseases. The types of diseases that can be treated with the present invention include, but are not limited to, the following: diseases associated with PTPase activity, immune deficiency, cancer, infections (such as viral infections), hepatitis B, and hepatitis C. The types of cancers that the present embodiment can be used to treat include those such as lymphoma, multiple myeloma, leukemia, melanoma, prostate cancer, breast cancer, renal cancer, bladder cancer. The therapeutic composition enhances cytokine activity. The therapeutic composition may include a cytokine, such as interferon α, interferon &bgr;, interferon γ, or granulocyte/macrophage colony stimulating factor.

公开(公告)号：EP0910388B1

公开(公告)日：2002-09-18

申请号：EP97916696.4

申请日：1997-03-27

申请人： Krotkiewski, Marcin

发明人： Krotkiewski, Marcin

IPC分类号： A61K31/715 ,  A61K31/29 ,  A61K33/24

CPC分类号： A61K31/715 ,  A61K33/24 ,  A61K31/29 ,  A61K2300/00

摘要： Pharmaceutical preparation containing a mixture of a bismuth citrate and an alginate and any reaction products obtained, especially bismuth alginate for the treatment of gastritis, reflux oesophagitis, duodenitis, dyspepsia and ulcer disease. The preparation causes eradication of Campylobacter such as Helibacter pylori (HP) and it further actively prevents the reflux of the stomach content. It may further contain one or more antibiotic substances in order to give higher and more stable eradication rate. A calcium compound, e.g. calcium chloride may be added to the reaction medium to create microencapsulation beads of calcium alginate acting as a slow-release coating. The preparation may further contain an agent such as sodium bicarbonate causing a neutralisation of the gastric acid milieu and a foaming effect.

公开(公告)号：EP0865286A1

公开(公告)日：1998-09-23

申请号：EP96940570.0

申请日：1996-11-22

申请人： THE PROCTER & GAMBLE COMPANY

发明人： FITZGERALD, Jamesina, Anne

IPC分类号： A61K31 ,  A61K33

CPC分类号： A61K31/43 ,  A61K31/415 ,  A61K31/60 ,  A61K31/70 ,  A61K33/245 ,  A61K31/29 ,  A61K2300/00

摘要： The subject invention encompasses methods for prevention and treatment of a human or lower animal subject having a gastrointestinal disorder caused or mediated by one or more intestinal helminths comprising administering to the subject bismuth and one or more antimicrobials. The subject invention also encompasses compositions comprising bismuth and one or more antimicrobials for the prevention and treatment of a human or lower animal subject having a gastrointestinal disorder caused or mediated by one or more intestinal helminths.

公开(公告)号：EP0830134A1

公开(公告)日：1998-03-25

申请号：EP96915593.0

申请日：1996-05-08

申请人： THE PROCTER & GAMBLE COMPANY

发明人： FITZGERALD, Jamesina, Anne ,  LEDERBERG, Joshua

IPC分类号： A61K31 ,  A61K33 ,  A61P33

CPC分类号： A61K33/245 ,  A61K31/29 ,  A61K31/60 ,  Y02A50/492

摘要： The subject invention encompasses methods for the prevention and treatment of a human or lower animal subject having a gastrointesinal disorder caused or mediated by one or more parasitic protozoa comprising administering bismuth to the subject.

公开(公告)号：EP0221176B1

公开(公告)日：1994-09-14

申请号：EP86903757.2

申请日：1986-05-02

申请人： CHEMEX PHARMACEUTICALS, INC.

发明人： ALLEN, Larry, M.

IPC分类号： A61K33/30 ,  A61K31/315 ,  A61K31/70 ,  A61K31/185 ,  A61K31/05 ,  A61K31/12 ,  A61K31/675 ,  A61K31/71 ,  A61K33/24 ,  A61K31/505

CPC分类号： A61K31/29 ,  A61K9/0014 ,  A61K33/30 ,  A61K47/02 ,  A61K47/183 ,  A61K47/52 ,  A61K47/541 ,  A61K47/69 ,  Y10S514/946 ,  Y10S514/947 ,  A61K31/00 ,  A61K2300/00

摘要： A method of inducing a reservoir effect in skin and mucous membranes so as to enhance penetration and retention and reduce transdermal flux of topically applied therapeutic and cosmetic pharmacologically active agents. The invention also relates to topical treatment methods involving such reservoir effect enhancers, and to pharmaceutical compositions containing them.

公开(公告)号：EP0439453A1

公开(公告)日：1991-08-07

申请号：EP88908644

申请日：1988-09-29

申请人： BORODY THOMAS J

发明人： BORODY THOMAS JULIUS

IPC分类号： A61K31/29 ,  A61K31/415 ,  A61K31/43 ,  A61K31/60 ,  A61K31/65 ,  A61K33/24 ,  A61K45/06 ,  A61P1/00 ,  A61P1/04 ,  A61P31/04

CPC分类号： A61K31/70 ,  A61K33/245 ,  Y10S514/925 ,  A61K33/24 ,  A61K31/29 ,  A61K2300/00

摘要： La présente invention se rapporte à un procédé servant à éradiquer des troubles gastrointestinaux associés à des infections au Campylobacter pylori et/ou empêcher leur récurrence. Ledit procédé consiste à administrer une composition pharmaceutique comprenant un composé de bismuth pharmaceutiquement acceptable avec un premier antibiotique et un second antibiotique. La présente invention se rapporte également à une composition pharmaceutique servant au traitement de troubles gastrointestinaux associés au C. pylori et à des compositions pharmaceutiques servant dans un tel traitement et conditionnées de façon à permettre une administration séquentielle.